Navigation Links
Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
Date:10/9/2008

CALGARY, Oct. 9 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 16th Annual BioPartnering Europe conference in London, U.K. on Monday, October 13 at 2 p.m. The conference is taking place at the Queen Elizabeth II Conference Centre from October 12-14, 2008.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

The presentation time is subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
2. Cell Therapeutics Provides Details on Investor & Media Day to be Held in Milan, Italy on Friday, October 3, 2008
3. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
4. U.S. News Media Group Releases 19th Edition of Americas Best Hospitals
5. VIDEO from Medialink and Med-El: New Technology is Music to Peoples Ears
6. BioLife Solutions Announces FDA Master File Acceptance for CryoStor(TM) Pre-formulated Cryopreservation Media
7. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
8. Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008
9. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
10. Intellisphere Announces Acquisition of Multiple Titles from Ascend Medias Healthcare Division
11. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., ST.LOUIS,Nov.24/PRNewswire-FirstCall/--Sigma-...ttheNASDAQOMXconferenceonTuesday,December1stat1:45...tenvialiveaudiobroadcastovertheInternetavailableat...Userscanclickthe"Webcast"icontoaccessthisfile. ,...ifeScienceandHighTechnologycompany.Itschemicalandb...
(Date:11/24/2009)..., SHANGHAI,Nov.24/PRNewswire-Asia/--NODPharmace...ce(PTO)hasallowedthepatentapplicationfor,itsnano-p...nologyisahighlyefficientapproachtoincorporatepepti...leoraldeliveryofdrugs,otherwiseadministeredasinjec...appliedtomanymacromoleculardrugssuchasinsulin,inte...
(Date:11/24/2009)..., SEATTLE,Nov.24/PRNewswire/--BlueMarbleEnergyC...DevelopmentAuthority(OPDA)wererecentlyawarded$2mil...tionBoard(CERB)inaprivate/publicpartnershiptoconst...inLincolnCounty,WA. ,, "Thisinvestmentwillsigni...gover70greenjobstoLincolnCounty,"saidBlueMarbleEne...
(Date:11/24/2009)..., TSXVENTURE:HTL , TORONTO,Nov.24/PRNewswi...lyCalottoCapitalInc.,aleadingproviderofadvancedlas...rtilityclinicmarkets,todayreportedoperationalandfi...009. , ,Q32009Highlights,-Revenuewas$1.46million...nwas66.3percentcomparedwith66.1percentinQ3,2008,-N...
Breaking Biology Technology:Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7
...ril 15 /PRNewswire-FirstCall/ - Angiotech Pharmace...specialty pharmaceutical and,medical device compan...,position as a non-executive director of the Compa...n his numerous business pursuits and additional,bo...,s Board of Directors,since 2005. This position wi...
...udy shows naturally occurring antibodies contained...prit for Alzheimer,s disease, CHICAGO, April 15 ...and Baxter International Inc. (NYSE: BAX ) today,...ng natural antibodies,contained in GAMMAGARD LIQUI...keted as KIOVIG in the European Union, a plasma-de...
...la., and CEDARHURST, N.Y., April 15 ,BioHorizons, ...n of its,purchase of Implant Logic Systems, Ltd. (...nt Logic Systems will operate as a subsidiary of,B...ented, "We are excited,to expand our product offer...ing software and CAD/CAM surgical guides. This acq...
Other Biology Technology:Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 2Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 3Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 4Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 5BioHorizons Announces the Purchase of Implant Logic Systems 2
(Date:11/24/2009)... Stents that keep weakened and flabby arteries fr...r six months, those stents are no longer needed --...nnecessary. Previously, doctors had no choice but ... of Tel Aviv University,s Department of Biomedical...ber platform that carries drugs where they,re need...
(Date:11/24/2009)..., BATON ROUGE Antarctica has long held secrets ...nd until recently, there has been very little info...beneath miles of ice for millions of years. Now, a...ding LSU have been funded to the tune of $10 mill... NSF, to get to the bottom of things literally. T...
(Date:11/23/2009)... CINCINNATINew research presents strong evidence ...re to both outdoor traffic-related pollution and i...gs than one or the other exposure alone. , Env...Cincinnati (UC) College of Medicine have shown tha...related particles and indoor endotoxin during earl...
Breaking Biology News(10 mins):A coating for life 2LSU gets to the bottom of things -- in Antarctica 2Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2American Academy of Pediatric Dentistry Releases New Perinatal and Infant Oral Health Guidelines 48437 1American Academy of Pediatric Dentistry Releases New Perinatal and Infant Oral Health Guidelines 48437 2American Academy of Pediatric Dentistry Releases New Perinatal and Infant Oral Health Guidelines 48437 3American Academy of Pediatric Dentistry Releases New Perinatal and Infant Oral Health Guidelines 48437 4Summer Travel Destinations are Heavy on Fun and Sun 48434 1Summer Travel Destinations are Heavy on Fun and Sun 48434 2Summer Travel Destinations are Heavy on Fun and Sun 48434 3Access Pharmaceuticals Announces Granting of Two US Patents for MuGard 28TM 29 12562 1Access Pharmaceuticals Announces Granting of Two US Patents for MuGard 28TM 29 12562 2Access Pharmaceuticals Announces Granting of Two US Patents for MuGard 28TM 29 12562 3
...13, 2008, 1:00 p.m. ET) Research published in Natu...hibitors of a cell death pathway, termed necroptos...that can direct cells into necrosis. Induced by tr...f necrotic death can result in tissue damage contr...ings present a novel avenue for drug development. ...
...is available in Spanish . , This research work ...mperature change. Their main goal has been to dete...mperatures in Spain, explained to SINC the researc... University of Granada and main author, Matthias...m temperature series of every month since the end ...
...April 11, 2008) World War II-era physiologists hel..., research that helped pave the way for an Allied ...he University of South Florida College of Medicine...rical research for Monday, April 7, at the Experim...ation is entitled High altitude physiology researc...
Other Biology News:Stopping unwanted cell death: Implications for drug discovery 2Stopping unwanted cell death: Implications for drug discovery 3Scientists compiled 20th century temperature data in Spain as evidence of climatic change 2USF professor gives historical look at physiology and WWII air war 2USF professor gives historical look at physiology and WWII air war 3
Death Check II Assay System (TUNEL/Cell Viability) from Promega
Bovine Serum from Innovative Research
Mouse Anti-Mouse Qa.m8 Monoclonal Antibody, Unconjugated, Clone 5035-24.1 from CEDARLANE Laboratories Limited
...edium are recommended for protein expression from ...mbination has been selected based on rapid, vigoro...observed specifically with baculoviruses derived f...Ready-Plaque Sf9 Cells and BacVector Insect Cell M...
Biology Products: